immuno-analytics

immuno-analytics integrates epitope mapping and genomic variant analyses to identify SARS-CoV-2 serological and vaccine targets and to monitor non-synonymous mutation distribution.

Key Features:

• Extensive Epitope Mapping and Prediction Meta-analysis: Provides meta-analyses of B-cell and T-cell epitope mapping and prediction for SARS-CoV-2 proteins.
• Updated Variant Database: Contains over 55,944 non-synonymous mutations derived from more than 16,087 whole genome sequences.
• Human Coronavirus Homology Mapping: Analyzes sequence homology between SARS-CoV-2 and other human coronaviruses to assess potential cross-reactivity.
• Geospatial Tracking of Mutations: Tracks over 7,800 non-synonymous mutation positions with geographic distribution and frequency.
• Integration with UniProt Database Annotations: Incorporates up-to-date UniProt annotations into protein-level analyses.

Scientific Applications:

• Vaccine Development: Identifies optimal B- and T-cell epitopes on SARS-CoV-2 proteins, such as the spike protein, to support vaccine candidate design and evaluation.
• Serological Diagnostics: Evaluates potential targets for serological assays, flags sub-optimal targets like the native nucleocapsid protein, and highlights alternatives such as orf3a for post-vaccine surveillance.
• Mutation Surveillance: Monitors temporal and geographic changes in mutation frequencies to inform viral evolution studies and public health surveillance.

Methodology:

Performs meta-analyses of epitope mapping and prediction and combines genetic data from whole genome sequences with immunological analyses; automated algorithms detect significant non-synonymous mutations and track their prevalence, compile the mutation database, map homology with other human coronaviruses, geospatially track mutation positions, and integrate UniProt annotations.